Portland-based Oregon Health & Science University recorded an operating income of $65 million (1.4% operating margin) through the third quarter of 2026, up from an operating loss of $71 million (-1.7% margin) during the same period last year.
OHSU reported total operating revenue of $4.7 billion for the nine months ended March 31, a 14.1% increase year over year. Net patient service revenue increased 20.6% to $3.4 billion. OHSU’s case mix index increased to 2.66 from 2.55, driven by a targeted expansion of services such as CAR-T, BMT, gene therapy and complex cardiac and neuro surgeries, which increased acuity and revenue.
Total operating expenses were $4.6 billion, a 10.6% increase year over year. Salaries, wages and benefits increased 11.3% to $2.8 billion, which includes previously delayed wage increases associated with various collective bargaining agreements. Services, supplies and other expenses grew 10.3% to $1.6 billion.
OHSU noted in its report that operating results have had “considerable month-to-month variability” amid a long-term trend in which payments per case are not keeping pace with rising labor, pharmacy and medical supply costs.
“Healthcare earnings are highly concentrated in a relatively small number of complex and high-cost cases that, depending on reimbursement, can impact an individual month’s results.”
OHSU reported a net income of $143.2 million through the third quarter of 2026, up from $24.2 million during the same period last year.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
